Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

Key Inclusion Criteria

• Lp(a) ≥ 70 mg/dL at the screening visit, measured at the Central laboratory

• Myocardial infarction: ≥ 3 months from screening and randomization to ≤ 10 years prior to the screening visit

• Ischemic stroke: ≥ 3 months from screening and randomization to ≤ 10 years prior to the screening visit

• Clinically significant symptomatic peripheral artery disease

Key Exclusion Criteria

• Uncontrolled hypertension

• Heart failure New York Heart Association (NYHA) class IV

• History of malignancy of any organ system

• History of hemorrhagic stroke or other major bleeding

• Platelet count ≤LLN

• Active liver disease or hepatic dysfunction

• Significant kidney disease

• Pregnant or nursing women

Other protocol-defined inclusion/exclusion criteria may apply at the end.